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Fig 1. Patients with grade II-IV acute GVHD, DC: Donor T-cell Chimerism, MC:
Mixed T-cell Chimerism. Diagonal pattern in bar indicates patients progressing
to steroid resistant (SR) GVHD. P¼0.007.
Table 1
Workup panel results of suspected Myositis.* 10 excluded due to lack of
testing from n¼68.
No. of
patients
Muscle Biopsy Enzymes+ Antibodies+ EMG+ MRI/PET+
7 Positive 6/7 4/7 7/7 2/2
2 Equivocal 2/2 0/2 1/1 1/1
5 Negative 1/5 0/3 4/4 0/3
44 Not Done 30/40 7/23 8/16 11/19
58* TOTAL 39/54 11/35 20/28 14/25
Fig-1. Number of patients meeting Myositis criteria.
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early predictor of development of steroid-resistant GVHD.
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Background: There is paucity of data on diagnostic criteria of
Myositis/Muscle chronic Graft-versus-Host disease [cGVHD]
due to rarity of the condition (<0.7% of all Allogeneic-
Hematopoietic-Stem-Cell-Transplants [HSCT]. Myalgias are
common after HSCT and confounding factors such as drugs
(statins, steroids etc.), infections (muscle abscess) and tumor
inﬁltration make diagnosis elusive. A diagnostic algorithm is
lacking.
Methods: We retrospectively analyzed all allogeneic-HSCTs
through the Mayo Clinic Database from Jan 1994-July 2013 to
search for cases of myositis in association with cGVHD using
terms “GVH”, “Muscle biopsy” and “Myositis”. Diagnostic
criteria utilized were 1) Muscle Biopsy; 2) Elevated Enzymes:
CK or Aldolase; 3) Serum Antibodies: ANA, anti-striated-
muscle, Anti Ro/Jo/La, Sm, Scl-70, RNP 4) EMG and 5) Imag-
ing: MRI or PET scan.
Results: Of 1058 screened allogeneic-HSCT, 68 were sus-
pected clinically of having myositis, mostly presenting as
focal or diffuse myalgias. 14 had muscle biopsies. 7 had
conﬁrmedmyositis (Age 43-66 yrs., median 47). Median time
to diagnosis was 19 months post-HSCT. All had cGVHD
involving at least one other organ. 5/7 had AML and 6/7
received a ﬂudarabine based conditioning. All biopsy positive
and 2 biopsy indeterminate patients met at least 2 additional
criteria besides biopsy (total criteria met 3). Of the 61 pa-
tients that were biopsy negative or not biopsied, none met 3
criteria (except 2 who could not be biopsied). 17 were tested
but met none of the criteria (excluded). Remaining met 2
criteria not deemed sufﬁcient for diagnosis. All biopsy
proven patients received prednisone treatment. 5 received
additional therapies including IVIG, ECP, Rituximab and
Sirolimus.
Conclusions: Muscle biopsy, while conﬁrmative, is invasive
and is rarely pursued (20%). Only half of the biopsies were
positive for myositis, likely due to patchy nature of theConﬂicts of Interest: Nonedisease. All biopsy proven myositis patients met 3 criteria.
Myositis as a component of cGVHD can be diagnosed using a
composite of autoantibodies, muscle enzymes, EMG and
imaging. This new criteria could be used to establish an al-
gorithm in delineating the need for muscle biopsy for sus-
pected myositis. (Fig 1 & Table 1).428
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Fig 1. Patients with hematologic relapse and no signs of cGVHD
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Background: Impacts of conditioning intensity and total
body irradiation (TBI) on acute graft-versus-host disease
(aGVHD) still remains a matter of debate, because the se-
lection of reduced intensity (RIC) or myeloablative condi-
tioning (MAC) is generally determined based on patient/
donor characteristics such as age, HLA mismatch, and donor
types.
Methods: We analyzed 5471 recipients (>15 years old) with
AML,ALL,CML or MDS who received allogeneic HCT between
2006 and 2009, using JSHCT registry database. Conditioning
is classiﬁed as High TBI(>8Gy)-MAC, Low TBI-MAC, nonTBI-
MAC, Low TBI-RIC and nonTBI-RIC. The impact of the types of
conditioning on aGVHD and other outcomes were assessed.
Subgroup analyses were also performed according to donor
types: HLA-matched related (MRD, n¼1374), HLA-mis-
matched related (MMRD, n¼429), HLA matched unrelated
(MUD, n¼1508), HLA mismatched unrelated donor (MMUD,
n¼820), and cord blood (CBT, n¼1340).
Results: The High TBI-MAC group included younger age and
more acute lymphoblastic leukemia. The Low TBI-MAC and
-RIC groups included more CBT and HLA mismatched BMT/
PBSCT. There was a signiﬁcant difference in the incidence of
aGVHD2-4: 39% in High TBI-MAC, 41% in Low TBI-MAC, 31%
in nonTBI-MAC, 37% in Low TBI-RIC, and 32% in nonTBI-RIC,
respectively (P<0.001). In multivariate analysis, TBI-con-
taining conditionings were signiﬁcantly associated with an
increased risk of aGVHD2-4: HR was 1.34 in High TBI-MAC
(P<0.001),1.50 in Low TBI-MAC (P<0.01),1.23 in Low TBI-RIC
(P¼0.011), and 1.21 in nonTBI-RIC (P¼0.051) in comparison
with nonTBI-MAC. Subgroup analyses revealed that the
adverse impact of High TBI-MAC on aGVHD2-4 was observed
only in HLA-matched BMT/PBSCT and CBT (HR¼1.61 in MRD,
P<0.001; HR¼1.44 in MUD, P<0.01; HR¼1.76 in CBT,
P¼0.042), while it disappeared in HLA-mismatched BMT/
PBSCT (HR¼0.72 in MMRD, P¼0.72; HR¼1.16 in MMUD,
P¼0.35). Other conditionings had no signiﬁcant impact on
aGVHD2-4 in subgroup analyses. For non-relapse mortality, a
favorable impact of High TBI-MAC was observed in MMUD
(HR¼0.66 in High TBI-MAC, P¼0.027), while any adverse
impact of TBI-conditioning on relapse/NRM was not
observed in any donor types. Finally, the conditioning types
had no impact on overall survival (OS) in MRD, MUD, and
CBT. Conversely, favorable impacts of TBI-conditioning on OS
were observed in MMRD (High TBI-MAC, HR¼0.54, P<0.01;
Low TBI-RIC, HR¼0.48, P<0.01) and MMUD (High TBI-MAC,
HR¼0.72, P¼0.026; Low TBI-RIC, HR¼0.65, P¼0.015) in
comparison with nonTBI-MAC. However, the impact of Low
TBI-RIC was not different from that of nonTBI-RIC, when we
focused only on RIC.
Conclusion: The adverse impact of High TBI-MAC on
aGVHD2-4 incidence was observed only in HLA-matched
BMT/PBSCT and CBT, but not in mismatched BMT/PBSCT. In
mismatched HCT, High TBI-MAC rather had a favorable
impact on OS and should not be avoided as long as there is no
contraindication.Fig 2. Reversion of declining CD34+ speciﬁc donor chimerism in 2 patients
with extensive chronic GVHD429
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Introduction: Success of allogeneic hematopoietic stem cell
transplant (allo-HSCT) for patients with acute myeloid leu-
kemia (AML) and myelodysplastic syndromes (MDS) largely
depends on graft versus leukemia (GVL) effect. Although GVL
cannot be directly measured in the clinical setting, its
development is frequently associated with the development
of chronic graft versus host disease (cGVHD). Here we
describe the assay, which allows monitoring of both minimal
residual disease (MRD) and GVL in MDS and AML patients
after allo-HCT.
Methods: MRD was monitored in high risk patients with
CD34+ MDS and AML by monthly peripheral blood CD34+
speciﬁc donor chimerism (PB CD34+ DC) analysis starting at
day +30 following allo-HCT. To obtain PB CD34+ DC, CD34+
cells were positively selected by immunomagnetic isolation
from peripheral blood followed by ﬂuorescence-activated
cell sorting. Highly puriﬁed CD34+ cells (>95%) were sub-
sequently evaluated for percentage of donor DNA contribu-
tion by short tandem repeat analysis.
Results: Between September 2011 and July 2013 subjects
with MDS or AML were monitored monthly by PB CD34+ DC
analysis. A rapid and steady decline in CD34+ donor chime-
rism was detected in all study participants who developed
